Marker for early diagnosis of sepsis-related diseases and application thereof
By detecting the PAX5 level in peripheral blood immune cells and using PAX5 as a biomarker, the early diagnosis and prognosis judgment of sepsis are achieved, the problem of early diagnosis difficulties in the prior art is solved, and the intervention time and patient survival rate are improved .
Patent Information
- Application Number
- CN202410977801.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to diagnose sepsis early before organ dysfunction, resulting in delayed intervention time and affecting patient survival.
Using PAX5 as a biomarker, assists in the early diagnosis of sepsis by detecting PAX5 levels in peripheral blood immune cells, providing early diagnosis, risk assessment, immune status assessment, prognosis prediction and treatment options for subject sepsis-related diseases. Selected products and methods.
It improves the accuracy and prognosis judgment of early diagnosis of sepsis, intervenes in sepsis in advance, improves patient survival, and diagnostic efficacy exceeds the commonly used clinical indicator PCT.
Smart Images

Figure CN118979104A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of molecular diagnosis, and relates to early diagnostic markers for sepsis-related diseases and uses thereof, and specifically to the use of PAX5 as a biomarker in the preparation of products for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment plans for sepsis-related diseases. Background Art
[0002] At present, the diagnosis of sepsis mainly relies on clinical indicators, and the diagnostic criteria are "infection + SOFA ≥ 2". The SOFA score, or Sequential Organ Failure Assessment (SOFA), is a scoring system that assesses the severity and prognosis of critically ill patients based on clinical blood biochemical tests and clinical indicators. The higher the score, the more severe the condition. The serum marker currently used to assist in the diagnosis of sepsis is procalcitonin (PCT). However, an increase in PCT only indicates infection, and it has a good distinction between infected and non-infected patients, but it is difficult to distinguish between common infections and sepsis. In summary, due to the lack of sepsis-specific molecular markers, it is difficult for clinicians to make early diagnosis and identification before the onset of organ dysfunction (SOFA ≥ 2). Early intervention is a universal principle for the treatment and management of sepsis. For every hour of delay in treatment, the patient's survival rate will decrease by about 7.6% (Ferrer, R., et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. American journal of respiratory and critical care medicine 180, 861-866 (2009).; Kumar, A., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine 34, 1589-1596 (2006).). If a new molecular marker of sepsis can be found, the occurrence of sepsis can be warned and diagnosed through its test results before organ dysfunction occurs, and the time window for intervention in sepsis can be advanced, so that patients can receive more timely treatment.
[0003] Chinese patent application CN118050527A discloses that neutrophil gelatinase-associated lipid transporter protein 2 or a combination of neutrophil gelatinase-associated lipid transporter protein 2 and matrix Gla protein can be used as a protein marker for diagnosing sepsis, with high diagnostic efficacy, an area under the curve of 0.903, good sensitivity and specificity, and can be developed into a kit for diagnosing sepsis, which can diagnose sepsis at an early stage and enable patients to receive timely and accurate treatment.
[0004] Chinese patent application CN117965718A discloses a biomarker related to sepsis and its application, wherein the biomarker is tiRNA-1:34-Lys-CTT-5, which can be used to prepare a product for early diagnosis and / or prognosis evaluation of sepsis. The product performs non-diagnostic detection of the expression level of tiRNA-1:34-Lys-CTT-5 in the test sample, thereby performing early diagnosis and / or prognosis evaluation of sepsis. The diagnostic value of tiRNA-1:34-Lys-CTT-5 for sepsis is higher than that of inflammatory mediators such as IL-6, IL-10, and TNF-α, which improves the accuracy of early diagnosis of sepsis; in addition, the area under the curve (AUC) of the receiver operating characteristic curve (ROC curve) for evaluating the prognosis of sepsis is significantly improved, which helps clinicians to adjust the treatment plan in time for the biomarker and improve the survival rate of patients.
[0005] Currently, the art needs more biomarkers or reagents for early diagnosis of sepsis. Summary of the invention
[0006] The present invention discloses an application for detecting PAX5 in peripheral blood immune cells of infected patients, and for the first time discovered the difference in expression of PAX5 in peripheral blood immune cells of sepsis patients and normal people, and this indicator can be used as a molecular marker for the diagnosis of sepsis. Peripheral blood is one of the most easily obtained clinical specimens, and detecting the level of PAX5 in peripheral blood immune cells can assist in the early diagnosis of sepsis.
[0007] In order to achieve the above technical objectives, the present invention proposes the following technical solutions:
[0008] In a first aspect, the present invention provides the use of PAX5, or an active fragment or a functional fragment thereof, in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction (or assessment, judgment) and / or treatment regimen selection of a subject for a sepsis-related disease.
[0009] In some embodiments, the PAX5 is used as a biomarker.
[0010] In some embodiments, the early stage of the sepsis-related disease is SOFA<2.
[0011] In some embodiments, the subject has a confirmed infection or a suspected infection.
[0012] In some embodiments, the sepsis-related disease comprises sepsis, severe sepsis, or septic shock.
[0013] In some preferred embodiments, the sepsis-related disease is sepsis.
[0014] In some embodiments, the article of manufacture comprises a reagent, kit, and / or detection device for determining the level of PAX5 in a sample from a subject.
[0015] In some embodiments, the sample is from a subject's bodily fluids, cells, tissues, metabolites, and / or excreta.
[0016] In some preferred embodiments, the sample is from a body fluid of a subject, selected from at least one of the following:
[0017] Blood, plasma, extracellular fluid, tissue fluid, lymph or cerebrospinal fluid.
[0018] In some more preferred embodiments, the sample is from the subject's blood, preferably peripheral blood.
[0019] In some preferred embodiments, the reagent or kit is selected from or comprises at least one of the following:
[0020] Primers, probes, antibodies, biochips (such as protein chips, gene chips, etc.), and small molecule compounds for specific detection of PAX5.
[0021] In some preferred embodiments, the detection device is compatible with the method of use of the reagent or kit, for example: a detection device for real-time quantitative reverse transcription PCR, biochip detection, Southern blotting, Northern blotting in situ hybridization, immunofluorescence, immunohistochemistry, or Northern blotting or in situ hybridization.
[0022] In some preferred embodiments, the agent is directly or indirectly labeled with a detectable label, and the detectable label is selected from at least one of the following:
[0023] Radioisotope, fluorescent group, chemiluminescent moiety, enzyme, enzyme substrate, enzyme cofactor, enzyme inhibitor, dye, metal ion, or ligand.
[0024] In some embodiments, the PAX5 is a substance selected from the group consisting of:
[0025] PAX5 gene, PAX5 mRNA, cDNA of PAX5 mRNA or PAX5 protein.
[0026] In some embodiments, the PAX5 level includes the PAX5 nucleic acid molecule level and / or the PAX5 protein molecule level.
[0027] In some embodiments, the subject is a mammal, such as a human, a non-human primate, preferably a human.
[0028] In a second aspect, the present invention provides a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction (or assessment, judgment) and / or treatment regimen selection of a subject's sepsis-related disease, the product comprising a reagent, kit and / or detection device for detecting the level of PAX5 in a sample from the subject.
[0029] In some embodiments, the PAX5 is used as a biomarker.
[0030] In some embodiments, the early stage of the sepsis-related disease is SOFA<2.
[0031] In some embodiments, the subject has a confirmed infection or a suspected infection.
[0032] In some embodiments, the sepsis-related disease comprises sepsis, severe sepsis, or septic shock.
[0033] In some embodiments, the sample is from a subject's bodily fluids, cells, tissues, metabolites, and / or excreta.
[0034] In some preferred embodiments, the sample is from a body fluid of a subject, selected from at least one of the following:
[0035] Blood, plasma, extracellular fluid, tissue fluid, lymph or cerebrospinal fluid.
[0036] In some more preferred embodiments, the sample is from the subject's blood, preferably peripheral blood.
[0037] In some preferred embodiments, the reagent or kit is selected from or comprises at least one of the following:
[0038] Primers, probes, antibodies, biochips (such as protein chips, gene chips, etc.), and small molecule compounds for specific detection of PAX5.
[0039] In some preferred embodiments, the detection device is compatible with the method of use of the reagent or kit, for example: a detection device for real-time quantitative reverse transcription PCR, biochip detection, Southern blotting, Northern blotting in situ hybridization, immunofluorescence, immunohistochemistry, or Northern blotting or in situ hybridization.
[0040] In some preferred embodiments, the agent is directly or indirectly labeled with a detectable label, and the detectable label is selected from at least one of the following:
[0041] Radioisotope, fluorescent group, chemiluminescent moiety, enzyme, enzyme substrate, enzyme cofactor, enzyme inhibitor, dye, metal ion, or ligand.
[0042] In some embodiments, the PAX5 is a substance selected from the group consisting of:
[0043] PAX5 gene, PAX5 mRNA, cDNA of PAX5 mRNA or PAX5 protein.
[0044] In some embodiments, the PAX5 level includes the PAX5 nucleic acid molecule level and / or the PAX5 protein molecule level.
[0045] In some embodiments, the subject is a mammal, such as a human, a non-human primate, preferably a human.
[0046] In some preferred embodiments, the product is a kit.
[0047] In some more preferred embodiments, the kit comprises:
[0048] (i) detecting an effective amount of a reagent for detecting PAX5 in a sample of a subject;
[0049] (ii) optionally, at least one substance selected from the following group:
[0050] Container or packaging, auxiliary agent, solution, buffer, negative control substance, positive control substance or instructions.
[0051] In some more preferred embodiments, the kit includes, but is not limited to: one or more of: Western blot kit, enzyme-linked immunosorbent assay (ELISA) kit, radioimmunoassay (RIA) kit, radial immunodiffusion kit, two-dimensional two-phase immunodiffusion kit, rocket immunoelectrophoresis kit, immunohistochemistry staining kit, immunoprecipitation assay kit, complement fixation assay kit, fluorescence activated cell sorting (FACS) kit, aptamer chip kit, microarray kit, protein chip kit, qPCR kit, and flow cytometry kit.
[0052] In a third aspect, the present invention provides a system for early diagnosis, risk assessment, immune status assessment, prognosis prediction (or assessment, judgment) and / or treatment regimen selection of a subject's sepsis-related disease, the system comprising:
[0053] (1) a first device for collecting and / or receiving data on PAX5 levels in a sample from a subject;
[0054] (2) a second device for analyzing the data to evaluate early diagnosis of sepsis-related diseases, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection for the subject;
[0055] Wherein, an increased level of PAX5 in the sample compared with a normal control value and / or a common infection value indicates that the subject suffers from a sepsis-related disease, or is at risk of developing a sepsis-related disease, or is at risk of immunosuppression, or is at risk of a poor prognosis.
[0056] In some embodiments, the early stage of the sepsis-related disease is SOFA<2.
[0057] In some embodiments, the subject has a confirmed infection or a suspected infection.
[0058] In some embodiments, the sepsis-related disease comprises sepsis, severe sepsis, or septic shock.
[0059] In some embodiments, the sample is from a subject's bodily fluids, cells, tissues, metabolites, and / or excreta.
[0060] In some preferred embodiments, the sample is from a body fluid of a subject, selected from at least one of the following:
[0061] Blood, plasma, extracellular fluid, tissue fluid, lymph or cerebrospinal fluid.
[0062] In some more preferred embodiments, the sample is from the subject's blood, preferably peripheral blood.
[0063] In some embodiments, the PAX5 level includes the PAX5 nucleic acid molecule level and / or the PAX5 protein molecule level.
[0064] In some embodiments, the PAX5 is a substance selected from the group consisting of:
[0065] PAX5 gene, PAX5 mRNA, cDNA of PAX5 mRNA or PAX5 protein.
[0066] In a fourth aspect, the present invention provides a method for early diagnosis, risk assessment, immune status assessment, prognosis prediction (or assessment, judgment) and / or treatment regimen selection of a subject for a sepsis-related disease, the method comprising:
[0067] 1) collecting and / or processing a sample from a subject to make the level of PAX5 detectable;
[0068] 2) using any of the aforementioned products or systems to detect the PAX5 level in a subject;
[0069] 3) Interpretation of results and prediction analysis;
[0070] Wherein an increased level of PAX5 in the sample compared with a normal control value and / or a common infection value indicates that the subject suffers from a sepsis-related disease, or is at risk of developing a sepsis-related disease, or is at risk of immunosuppression, or is at risk of a poor prognosis.
[0071] In some embodiments, the early stage of the sepsis-related disease is SOFA<2.
[0072] In some embodiments, the subject has a confirmed infection or a suspected infection.
[0073] In some embodiments, the sepsis-related disease comprises sepsis, severe sepsis, or septic shock.
[0074] In some embodiments, the sample is from a subject's bodily fluids, cells, tissues, metabolites, and / or excreta.
[0075] In some preferred embodiments, the sample is from a body fluid of a subject, selected from at least one of the following:
[0076] Blood, plasma, extracellular fluid, tissue fluid, lymph or cerebrospinal fluid.
[0077] In some more preferred embodiments, the sample is from the subject's blood, preferably peripheral blood.
[0078] In some embodiments, the PAX5 level includes the PAX5 nucleic acid molecule level and / or the PAX5 protein molecule level.
[0079] In some embodiments, the PAX5 is a substance selected from the group consisting of:
[0080] PAX5 gene, PAX5 mRNA, cDNA of PAX5 mRNA or PAX5 protein.
[0081] The present invention uses a variety of sequencing analysis methods, blood sample detection of clinically infected patients, and tracking of the clinical outcomes of these infected patients to identify that the PAX5 molecule shows obvious expression changes in the early stages of sepsis, which can distinguish between infected and non-infected patients, and between patients with common infections and those who eventually progress to sepsis. It is expected to be used as a sepsis immune marker for early diagnosis of sepsis, immune status assessment, and prognosis judgment. PAX5 has a good diagnostic efficacy, and the ROC analysis shows that the AUC is 0.8, which exceeds the diagnostic efficacy of the commonly used clinical indicator PCT. Therefore, the sepsis biomarker provided by the present invention is of great significance for the diagnosis of early clinical sepsis, and also has good application in the in vitro diagnostic reagent industry. BRIEF DESCRIPTION OF THE DRAWINGS
[0082] Figure 1 The digital PCR was used to detect the levels of PAX5 mRNA in peripheral blood immune cells of healthy volunteers, patients with common infections and patients with sepsis.
[0083] Figure 2 The ROC curve is shown to analyze the diagnostic efficacy of PAX5, indicating that PAX5 can effectively distinguish between patients with common infections and patients with sepsis.
[0084] Figure 3 The ROC curve is shown for survival and prognosis analysis of 176 sepsis patients in the sequencing data set E-MTAB-7581 of the Biostudies database, indicating that PAX5 has a good predictive efficacy (AUC=0.8).
[0085] Figure 4 The Kaplan-Meier survival curve is shown for survival and prognosis analysis of 479 sepsis patients in the sequencing data set GSE65682 of the GEO database, indicating that the expression level of PAX5 can predict the prognosis and survival of patients.
[0086] Figure 5 The figure shows the expression of PAX5 in peripheral blood immune cells analyzed by flow cytometry. DETAILED DESCRIPTION
[0087] In order to make the purpose, technical solution and advantages of the embodiments of the present disclosure clearer, the technical solution of the embodiments of the present disclosure will be clearly and completely described below in conjunction with the drawings of the embodiments of the present disclosure. Obviously, the described embodiments are part of the embodiments of the present disclosure, not all of the embodiments. Based on the described embodiments of the present disclosure, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0088] The present invention may be implemented in other specific forms without departing from the basic attributes of the present invention. It should be understood that, without conflict, any and all embodiments of the present invention may be combined with the technical features in any other embodiment or multiple other embodiments to obtain other embodiments. The present invention includes other embodiments obtained by such combination.
[0089] All publications and patents mentioned in this disclosure are hereby incorporated by reference into this disclosure in their entirety. If the purposes or terms used in any publications and patents incorporated by reference conflict with the purposes or terms used in this disclosure, then the purposes and terms of this disclosure shall prevail.
[0090] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0091] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.
[0092] Unless the context clearly dictates otherwise, the expressions "a", "an" and "an" as used herein include plural references. For example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth.
[0093] As shown in the present disclosure, the term "about" means a range of ±20% of the value thereafter. In some embodiments, the term "about" means a range of ±10% of the value thereafter. In some embodiments, the term "about" means a range of ±5% of the value thereafter.
[0094] The numerical ranges used in the present disclosure should be understood to have enumerated all the numbers within the range. For example, a range of 1 to 20 should be understood to include any number, combination of numbers, or subrange from the following group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
[0095] As used in this disclosure, the term "comprises" or "comprising" means "including but not limited to". The term is intended to be open-ended to specify the presence of any stated features, elements, integers, steps, or components, but does not exclude the presence or addition of one or more other features, elements, integers, steps, components, or groups thereof. Therefore, the term "comprising" includes the more restrictive terms "consisting of" and "consisting essentially of". In one embodiment, the term "comprising" used throughout the disclosure, especially in the claims, may be replaced by the term "consisting of".
[0096] As used herein, the terms "optional", "either", "any", or "any" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs or does not occur. As used herein, "a" and "an" are used herein to refer to one or more than one of the grammatical objects.
[0097] As shown in the present disclosure, “and / or” should be understood to mean any one of the optional items or a combination of any two or more of the optional items.
[0098] The term "sepsis-related disease" used in the present disclosure refers to a class of diseases of life-threatening organ dysfunction caused by a disordered host response to infection, including, but not limited to, sepsis, septic shock, and severe sepsis. In some preferred embodiments, the sepsis-related disease is sepsis. The specific definition and diagnostic criteria of sepsis can be found in Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315 (8): 801-810. doi: 10.1001 / jama.2016.0287.
[0099] The term "PAX5" used in the present disclosure refers to a family of genes that control paired regions of important transcription factors in human embryonic development. The PAX5 gene is a nuclear trans-transcription factor first discovered in B cells by Barberis et al. (Barberis A, Superti-Furga G, Vitelli L, et al. Developmental and tissue-specific regulation of a novel transcription factor of the sea urchin [J]. Genes Dev. 1989, 3 (5): 663-675) in 1989. It is located on chromosome 9p13 and encodes B cell-specific activator protein (BSAP), which controls organ formation and tissue differentiation (Carotta S, Holmes ML, Pridans C, et al. Pax5 maintains cellular identity by repressing gene expression throughout B cell differentiation [J]. Cell Cycle. 2006, 2452-2456.), and plays an important role in the early stages of B cell formation, neurogenesis, spermatogenesis, and inhibition of osteoclast formation.
[0100] The terms "reagent", "detection reagent" or "reagent for detecting PAX5 levels" used herein are used interchangeably and refer to substances that are specific to the PAX5 molecule and can be used to directly or indirectly detect the presence and / or content of the PAX5 level. These detection substances can detect PAX5 at the gene level or protein level. According to the sequence of the PAX5 molecule, a person of ordinary skill in the art can prepare or obtain a reagent that is specific to the PAX5 molecule based on conventional means. For example, the detection reagents available in this application include, but are not limited to: antibodies (preferably monoclonal antibodies), probes, gene chips, PCR primers, gRNA, etc. that have detection specificity for the PAX5 molecule. In addition, in order to facilitate detection, the detection reagents disclosed in the present invention may also carry a detectable label, and the detectable label includes, but is not limited to: radioactive isotopes, fluorophores, chemiluminescent moieties, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, ligands (such as biotin or haptens), etc. The detection reagent disclosed herein can be present in a solution, fixed on a carrier (such as a substrate, an adsorbent), or in other conventional forms in the art, as long as the form of existence is suitable for detecting PAX5 in a biological sample. For example, when the detection reagent of the present invention is a nucleotide probe, it can be present in the form of a biochip (or "microarray").
[0101] The terms "product" or "detection product" used herein are used interchangeably, and refer to a combination of substances or reagents that specifically target PAX5, or their combined use, auxiliary use, and the like. According to the needs of the detection method used, an appropriate PAX5 detection substance can be selected and made into a product suitable for the detection method used, such as a kit. A person of ordinary skill in the art can adjust and change the detection method and the reagents contained in the product according to actual conditions and needs. The product disclosed herein may also include other reagents that are clinically used for early diagnosis of sepsis-related diseases in subjects, risk assessment, immune status assessment, prognosis prediction (or assessment, judgment) and / or treatment regimen selection, to assist or verify the results obtained by detecting PAX5. A person of ordinary skill in the art can make routine selections according to specific needs.
[0102] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiment. In the embodiment, if specific conditions are not specified, the conditions are carried out according to normal conditions or manufacturer's recommendations. If all reagents or instruments are not specified by the manufacturer, they are all conventional products that can be purchased commercially. In order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concept of the present invention.
[0103] Example 1: Validation of the clinical diagnostic efficacy of PAX5 for distinguishing common infections from sepsis
[0104] The present invention recruited 40 patients with common infections, 11 patients with sepsis and 20 healthy volunteers as normal controls from West China Hospital of Sichuan University, collected their peripheral blood immune cells, and analyzed the PAX5 mRNA level by PCR.
[0105] Digital PCR was used to detect the levels of PAX5 mRNA in peripheral blood immune cells of healthy volunteers (n=20), patients with common infections (n=40), and patients with sepsis (n=11); the differences among the groups were compared using one-way ANOVA test, and the differences between the common infection group and the sepsis group were compared using Mann-Whitney u test (p<0.0001)( Figure 1 ).
[0106] Digital PCR detection of the absolute expression of PAX5 in the patient's peripheral blood: Bio-Rad's QX200 ddPCR instrument was used to detect the absolute copy number of gene mRNA. The QX200 ddPCR system mainly uses microfluidics technology to achieve large-scale partitioning of samples to be tested. Each sample will be prepared into about 20,000 nano-scale droplet molecules before testing. The specific steps are as follows:
[0107] (1) Extraction of total RNA.
[0108] Peripheral blood collected in EDTA-containing anticoagulant tubes was lysed overnight (-80°C) or on ice for 30 minutes by adding an appropriate volume of Trizol in an enzyme-free environment.
[0109] Thaw the lysed blood at room temperature, mix it by inversion, and let it stand at room temperature for 10 minutes. Add 1 / 5 of the sample volume (about 200 μL) of chloroform. Vortex mix for 30 seconds and let it stand for 5 minutes. Pink can be observed in the lower layer and colorless in the upper layer.
[0110] Centrifuge at 12,000 g for 20 min in a 4 °C centrifuge.
[0111] After centrifugation, the sample can be clearly divided into three layers: the pink protein is at the bottom layer, the white DNA is in the middle layer, and the RNA is at the top colorless water layer; carefully pipette the RNA into a new enzyme-free tube.
[0112] Add an equal volume of isopropanol, mix it with RNA, and transfer them to -20°C, waiting for RNA precipitation (about 1-2 hours); after centrifugation at 12000g for 10 minutes at 4°C, white block-like RNA precipitate can be seen at the bottom of the tube.
[0113] Remove the supernatant and add prepared DEPC (alcohol:DEPC=3:1) to the precipitate to resuspend the RNA;
[0114] Centrifuge at 4°C, 12,000 g, 5 min, repeat twice.
[0115] After washing away the supernatant, air-dry the RNA in a fume hood. When the precipitate becomes colorless and transparent, add 30 μL of enzyme-free water, mix thoroughly, and measure the RNA concentration using the Thermo Scientific Nanodrop.
[0116] Reverse transcription. Removal of genomic DNA: Add 1 μg of qualified RNA to the following reaction system, gently pipette to mix, then transfer the prepared reaction mixture to a metal bath and react at 42°C for 2 minutes.
[0117] Table 1 Genome removal reaction system
[0118]
[0119] Take out the mixture after the reaction from the metal bath, and prepare the reverse transcription reaction system according to the composition in the table below. After completion, put the mixture into the PCR instrument for reverse transcription. The reverse transcription program is: 37℃, 15 minutes; 85℃, 2 minutes; 4℃ insulation.
[0120] Table 2 Reverse transcription reaction system
[0121]
[0122]
[0123] (3) After reverse transcription is completed, the obtained cDNA concentration is diluted to about 0.2 ng / μL RNA equivalent, and the ddPCR reaction system of the gene to be tested is prepared: 1 μL cDNA template, Bio-rad's QX200TM ddPCR TM 10 μL of enzyme premix reaction solution, 0.8 μL of primers (0.4 μL each for forward and reverse primers) and water are added to make up to 20 μL system. The primer sequences of PAX5 involved in the present invention are: PAX5-F: ACTTGCTCATCAAGGTGTCAG (SEQ ID NO: 1); PAX5-R: TCCTCCAATTACCCCAGGCTT (SEQ ID NO: 2).
[0124] The results of the scatter bar graph showed that the PAX5 mRNA level in patients with common infections was significantly lower than that in healthy controls; and the PAX5 mRNA level in patients with sepsis was significantly lower than that in patients with common infections (p<0.0001) ( Figure 1 ).
[0125] The receiver operating characteristic (ROC) curve analysis of the diagnostic efficacy of PAX5 showed that the area under the curve (AUC) of the common infection group compared with the sepsis group was 0.9524, indicating that the PAX5 mRNA level had a high diagnostic efficacy in distinguishing sepsis from common infection (p<0.0001) ( Figure 2 ).
[0126] The above results show that PAX5, as a new biomarker, can well distinguish sepsis from common infections, and is expected to be used in clinical screening and diagnosis of patients with common infections and sepsis.
[0127] Example 2: Receiver operating characteristic curve (ROC) and Kaplan-Meier survival curve were used to evaluate the predictive efficacy of PAX5 on the prognosis of patients with sepsis
[0128] The present invention analyzes the sequencing data set E-MTAB-7581 (https: / / www.ebi.ac.uk / biostudies / arrayexpress / studies?query=E-MTAB-7581) of the public database Biostudies database. The data contains 176 patients with sepsis, and the expression of PAX5 and clinical outcome information of the patients are collected, and the receiver operating characteristic curve (ROC) analysis is performed. The process of drawing the ROC curve is to calculate the sensitivity (sensitivity), specificity (specificity) and false positive rate (1-specificity) of all cutoff points. The sensitivity is used as the ordinate to represent the true positive rate, and (1-specificity) is used as the abscissa to represent the false positive rate, and the ROC curve is drawn. The area under the curve (AUC) reflects the value of the diagnostic test. The larger the area, the closer it is to 1.0, the better the diagnostic efficacy and the higher the accuracy; the closer it is to 0.5, the lower the diagnostic efficacy; when it is equal to 0.5, it has no diagnostic value. On the ROC curve, the point on the upper left corner of the curve is often selected as the best cutoff value point, at which the corresponding sensitivity and specificity are relatively optimal. The ROC results show that the area under the curve AUC is 0.8, the sensitivity is 0.878, the specificity is 0.628, and the optimal cutoff value is 4.845, which has good accuracy and clinical application value ( Figure 3 ).
[0129] The present invention analyzes 479 sepsis patients with clinical prognosis information in the sequencing data set GSE65682 of the public database GEO database (https: / / www.ncbi.nlm.nih.gov / geo / query / acc.cgi?acc=GSE65682), collects the expression of PAX5 and clinical outcome information of the patients, and performs Kaplan-Meier survival curve analysis. The Kaplan-Meier survival curve is mainly used to analyze the impact of a single factor on survival, to estimate patient survival rate and to draw survival curves. The survival curve is a continuous step curve drawn with survival time as the horizontal axis and survival rate as the vertical axis to illustrate the relationship between survival time and survival rate. In the fields of medicine, biology, etc., Kaplan-Meier survival curves are often used to evaluate the prognosis of diseases, treatment effects, etc. Analysis shows that PAX5 expression is significantly correlated with the survival of sepsis patients ( Figure 4 ). The Kaplan-Meier survival curve was used to analyze the prognostic value of PAX5 for sepsis patients in the GSE65682 dataset. The results showed that the expression of PAX5 was significantly correlated with the survival rate of sepsis patients (p = 0.0017) ( Figure 4 ).
[0130] Example 3: Flow cytometry detection and verification of PAX5
[0131] 5.1: Flow cytometry detection and verification of PAX5
[0132] The present invention was also verified by flow cytometry, and it was found that compared with the healthy control group, the PAX5 protein level in the peripheral blood immune cells of the sepsis group was significantly reduced, which suggests that the detection of the PAX5 protein level in peripheral blood immune cells can also be used for the diagnosis of sepsis ( Figure 5 ).
[0133] 5.1.1: Construction of animal models
[0134] All wild-type C57 mice (SPF grade) of the present invention were purchased from Beijing Huafukang Biotechnology Co., Ltd. The age range of the mice was 7-8 weeks, and the weight range was 20g-25g. The purchased mice were all adaptively raised for one week in the Experimental Animal Center Building of the Frontier Medical Research Center of West China Hospital, Sichuan University. The breeding room was well ventilated, the humidity was 50%-60%, and the room temperature was controlled at about 26°C. The night and day were alternately 12 hours each day. The mice were fed with standard feed and had free drinking water; the experiment was carried out after one week of adaptive feeding.
[0135] Construction of severe infection (sepsis) model (referred to as sepsis group): 6-8 week old C57 black mice were selected and anesthetized with sodium pentobarbital. The abdominal skin of the mice was prepared with a shaver. After disinfection with iodine, the mice were opened under sterile conditions, i.e. a small incision was made 0.5 cm to the left of the midline of the abdomen. The cecum was separated and gently removed with surgical forceps (curved forceps), and then ligated with sterile No. 4 thread at 0.75 cm from the blind end. Then, an 18-gauge thick needle was used to pierce through it once, and then the cecum was returned to the abdominal cavity. The muscle layer and outer skin layer of the mice were sutured, and after disinfection with iodine, the mice were returned to the breeding cage for observation.
[0136] The healthy sham operation group (referred to as the control group) was used as a control: the left and right operations before laparotomy were consistent with the mild / severe model. Only after the laparotomy was found, the cecum was gently placed back into the abdominal cavity without ligation or puncture. The muscle layer and outer skin layer of the mice were sutured, and the mice were disinfected with iodine and returned to the breeding cage for observation.
[0137] All mice were immediately injected subcutaneously with 800 μL of normal saline for fluid rewarming after modeling, and 20 mg / kg of ciprofloxacin was injected intramuscularly in the thigh.
[0138] 5.1.2 Flow cytometry verification of PAX5 expression:
[0139] (1) A sepsis model was established according to the above animal modeling method, and the sham operation group (Sham) was used as the healthy control.
[0140] (2) Collect 50 μL of mouse peripheral blood into a K3EDTA blood anticoagulant tube and mix by inversion.
[0141] (3) Add flow cytometry antibodies for all genes to be tested according to the instructions (usually 2.5 μL / test): CD45 (Brand: BD Pharmingen TM , Catalog No.: 557659) Since there is no direct labeling flow cytometry antibody for PAX5, the primary antibody selected in the present invention is PAX5 (brand: Invitrogen; Catalog No.: PA1-109), and the secondary antibody DyLight 488 goat anti-rabbit IgG secondary antibody (Catalog No. 35552) is used at the same time. Then incubate at room temperature (20°C) in the dark for 15 minutes.
[0142] (4) Add 450 μL of 1× FACs hemolysin to the counting tube and incubate in the dark at room temperature (20°C) for 15 minutes to fully lyse the red blood cells.
[0143] (5) For flow cytometry detection, the sample does not need to be washed. DapI is added 5 minutes before the flow cytometer detection to perform cell live and dead staining, and then the sample can be loaded onto the instrument.
[0144] (6) Results Analysis
[0145] The FAC files downloaded from the flow cytometer were analyzed using Fiowjo 10.0.
[0146] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. Use of PAX5 or its active fragments or functional fragments in the preparation of products for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of a subject's sepsis-related disease; Preferably, the PAX5 is used as a biomarker; Preferably, the sepsis-related disease is in the early stage with SOFA <2; and / or, the subject is diagnosed with infection or suspected of infection; Preferably, the sepsis-related disease includes sepsis, severe sepsis or septic shock, more preferably sepsis; Preferably, the product comprises a reagent, a kit and / or a detection device for determining the level of PAX5 in a sample from a subject; Preferably, the sample is from body fluids, cells, tissues, metabolites and / or excreta of the subject; Preferably, the sample is from a body fluid of a subject and is selected from at least one of the following: Blood, plasma, extracellular fluid, tissue fluid, lymph or cerebrospinal fluid; More preferably, the sample is from the subject's blood; Most preferably, the sample is from peripheral blood of a subject.
2. The use according to claim 1, characterized in that The reagent or kit is selected from or comprises at least one of the following: Primers, probes, antibodies, biochips or small molecule compounds for specific detection of PAX5; and / or, the detection device is compatible with the method of use of the reagent or kit, for example: a detection device for real-time quantitative reverse transcription PCR, biochip detection, Southern blotting, Northern blotting in situ hybridization, immunofluorescence, immunohistochemistry, or Northern blotting or in situ hybridization; And / or, the reagent is directly or indirectly labeled with a detectable label, and the detectable label is selected from at least one of the following: Radioisotope, fluorescent group, chemiluminescent moiety, enzyme, enzyme substrate, enzyme cofactor, enzyme inhibitor, dye, metal ion, or ligand.
3. The use according to any one of claims 1 to 2, characterized in that: The PAX5 is a substance selected from the following group: PAX5 gene, PAX5 mRNA, cDNA of PAX5 mRNA, or PAX5 protein; And / or, the PAX5 level includes the PAX5 nucleic acid molecule level and / or the PAX5 protein molecule level.
4. A product for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of a subject's sepsis-related disease, characterized in that: The product comprises a reagent, a kit and / or a detection device for detecting the level of PAX5 in a sample from a subject; Preferably, the PAX5 level includes the PAX5 nucleic acid molecule level and / or the PAX5 protein molecule level; Preferably, the sepsis-related disease is in the early stage with SOFA <2; and / or, the subject is diagnosed with infection or suspected of infection; Preferably, the sepsis-related disease includes sepsis, severe sepsis or septic shock, more preferably sepsis; Preferably, the sample is from body fluids, cells, tissues, metabolites and / or excreta of the subject; Preferably, the sample is from a body fluid of a subject and is selected from at least one of the following: Blood, plasma, extracellular fluid, tissue fluid, lymph or cerebrospinal fluid; More preferably, the sample is from the subject's blood; Most preferably, the sample is from peripheral blood of a subject.
5. The product according to claim 4, characterized in that The reagent or kit is selected from or comprises at least one of the following: Primers, probes, antibodies, biochips or small molecule compounds for specifically detecting PAX5 levels; Preferably, the reagent is directly or indirectly labeled with a detectable label, and the detectable label is selected from at least one of the following: Radioisotope, fluorescent group, chemiluminescent moiety, enzyme, enzyme substrate, enzyme cofactor, enzyme inhibitor, dye, metal ion, or ligand.
6. The product according to claim 4 or 5, characterized in that The PAX5 is a substance selected from the following group: PAX5 gene, PAX5 mRNA, cDNA of PAX5 mRNA or PAX5 protein.
7. The product according to claim 6, characterized in that The product is a kit, which includes: (i) detecting an effective amount of a reagent for detecting PAX5 in a sample of a subject; (ii) optionally, at least one substance selected from the following group: Container or packaging, adjuvant, solution, buffer, negative control, positive control or instructions; Preferably, the kit comprises one or more of a Western blot kit, an enzyme-linked immunosorbent assay kit, a radioimmunoassay kit, a radial immunodiffusion kit, a two-dimensional two-phase immunodiffusion kit, a rocket immunoelectrophoresis kit, an immunohistochemistry staining kit, an immunoprecipitation assay kit, a complement fixation assay kit, a fluorescence-activated cell sorting kit, an aptamer chip kit, a microarray kit, a protein chip kit, a qPCR kit, and a flow cytometry kit.
8. A system for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of a subject's sepsis-related disease, characterized in that: The system comprises: (1) a first device for collecting and / or receiving data on PAX5 levels in a sample from a subject; (2) a second device for analyzing the data to evaluate early diagnosis of sepsis-related diseases, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection for the subject; Wherein, an increase in the PAX5 level in the sample compared with a normal control value and / or a common infection value indicates that the subject suffers from a sepsis-related disease, or is at risk of developing a sepsis-related disease, or is at risk of immunosuppression, or is at risk of a poor prognosis; Preferably, the sepsis-related disease is in the early stage with SOFA <2; and / or, the subject is diagnosed with infection or suspected of infection; Preferably, the sepsis-related disease includes sepsis, severe sepsis or septic shock, more preferably sepsis; Preferably, the sample is from body fluids, cells, tissues, metabolites and / or excreta of the subject; Preferably, the sample is from a body fluid of a subject and is selected from at least one of the following: Blood, plasma, extracellular fluid, tissue fluid, lymph or cerebrospinal fluid; More preferably, the sample is from the subject's blood; Most preferably, the sample is from peripheral blood of a subject.
9. The system according to claim 8, characterized in that The PAX5 level includes the PAX5 nucleic acid molecule level and / or the PAX5 protein molecule level.
10. The system according to claim 9, characterized in that The PAX5 is a substance selected from the following group: PAX5 gene, PAX5 mRNA, cDNA of PAX5 mRNA or PAX5 protein.
Citation Information
Patent Citations
Biomarker related to sepsis and application thereof
CN117965718A
Biomarker for diagnosing septicopyemia and application thereof
CN118050527A
Cited By
Application of reagent for detecting LGALS2 gene in preparation of product for diagnosing sepsis coagulopathy
CN120082643A
Histone modified marker combination for sepsis as well as application and kit of histone modified marker combination
CN120275641A
Application of CCL18 in preparation of sepsis-related lung injury diagnosis and prognosis evaluation product
CN120539429A
